Business Wire

Fujirebio further extends its fully automated blood-based biomarker portfolio with the fully automated Lumipulse ® G ApoE4 and Lumipulse ® G Pan-ApoE assays for Research Use Only

Share

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays for the fully automated LUMIPULSE® G Systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of the E4 isoform of the apolipoprotein E (ApoE4), specifically, and for all isoforms of the same protein (Pan-ApoE), respectively, in human plasma within just 35 minutes. The two new automated blood-based biomarker assays are available for Research Use Only.

“One year after the release of the first blood-based biomarkers for Alzheimer’s disease on our robust LUMIPULSE G platform, Fujirebio adds another two markers to its steadily growing portfolio,” said Christiaan De Wilde, CEO of Fujirebio Europe NV and Global Head Neuro Business. “These new assays will further support biomarker research in the field of neurodegenerative diseases, an important mission for Fujirebio.”

The Lumipulse G ApoE4 and the Lumipulse G Pan-ApoE assays complement the blood-based biomarker panel of RUO assays for β-amyloid1-42, β-amyloid1-40, phospho-Tau181 and neurofilament light, alongside five cerebrospinal fluid (CSF) based assays (β-amyloid1-42, β-amyloid1-40, total Tau, phospho-Tau181 and neurofilament light; all CE-IVDR, except for the latter) already available within the Lumipulse G Neuro product portfolio.

They will allow researchers and clinical research professionals across the world to further investigate the clinical utility of the ApoE protein quantification in Alzheimer’s disease and related disorders on the LUMIPULSE G platform. This platform has the required throughput and meets the regulatory requirements to support possible future routine use of blood-based testing of these markers. The APOE gene has three different alleles (ε2, ε3, ε4) that encode for three different ApoE isoforms (ApoE2, ApoE3, and ApoE4), resulting in 6 different phenotypes1. Molecular testing remains the gold standard for APOE genotyping, however quantification of the ApoE proteins using immunoassays could provide another piece of information, related to the expression levels of the proteins coded in the genes. There is hope that blood-based testing can become an even simpler, more accessible, and more scalable approach to help support the diagnosis of Alzheimer’s disease. In this regard, ApoE as a protein biomarker can be used in research to determine its value alone or as part of a panel of plasma biomarkers2.

The development of the Lumipulse G ApoE4 and Lumipulse G Pan-ApoE assays has been supported by the Flanders Innovation & Entrepreneurship (VLAIO).

About Fujirebio

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production, and worldwide commercialization of robust IVD products.

Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/alzheimer.

References:

  1. Emi M, et al. Genomics, 3(4):373-379, 1988.
  2. Palmqvist S, et al. Nat Med, 27(6):1034-1042, 2021.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media:
Public Relations Section, Public Relations/Sustainability Department,
H.U. Group Holdings, Inc..
Phone: +81-3-6279-0884
E-mail: pr@hugp.com

Christiaan De Wilde
CEO Fujirebio Europe
Phone: +32 9329 1703

For investors and analysts:
IR/SR Dept.
Phone: +81-3-5909-3337
E-mail: ir@hugp.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SmartStream Launches Latest Solution for Onboarding Cash Balances Faster With AI-Enabled Technology6.6.2023 09:53:00 CEST | Press release

SmartStream, the financial Transaction Lifecycle Management (TLM®) solutions provider, today announces the latest version of SmartStream Air – with new AI functionality to onboard cash balances faster and more accurately, whilst further improving cash reconciliations. A new development team was set up to research and provide the new functionality in partnership with clients. If cash balances and/or positions are not managed correctly they will eventually lead to errors, financial losses, and even regulatory penalties. The key USP for SmartStream Air version 8 is for quick and easy onboarding of cash balances. The latest solution will continue to leverage its AI-enabled technology and exception management capabilities to provide users with the confidence to manage cash balances instantly. It is a great addition for existing clients, whilst providing a competitive advantage by outperforming slow, expensive, and ineffective systems. Jethro MacDonald, Head of Product Management – AI and Ma

Chatham Hires Jennifer McLellan as a Managing Director in Global ISDA and Regulatory Practice6.6.2023 09:00:00 CEST | Press release

Chatham Financial, a global leader in financial risk management advisory and technology solutions, is pleased to announce Jennifer McLellan is joining the company as a Managing Director in the global OTC derivative instruments, ISDA and regulatory practice. Jennifer established a leading practice in 2011 for law firm Dickson Minto, where she was the Head of Derivatives before joining Chatham. She has advised private equity sponsors, their portfolio investments, UK listed and private corporates, and an array of investment fund boards and managers on the end-user legal and regulatory issues around derivatives. Jennifer brings hands-on knowledge in navigating complicated cross-border M&A leveraged deals, including some of the largest European LBOs. She has advised on all stages of the deal lifecycle including diligence, deal contingent structures, running competitive multi-bank interest rate and FX hedging processes, as well as financial restructuring. On the funds side, Jennifer has a we

Intelsat To Deliver 2Ku Connectivity Upgrade to Japan Airlines6.6.2023 09:00:00 CEST | Press release

Intelsat, operator of the world’s largest integrated satellite and terrestrial network and leading provider of Inflight Connectivity (IFC) services, has reached an agreement with long-time customer Japan Airlines (JAL) to upgrade about 50 Boeing 737s and 767s to the company’s 2Ku inflight connectivity solution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230606005202/en/ Intelsat To Deliver 2Ku Connectivity Upgrade to Japan Airlines (Photo: Business Wire) “We value the trust that JAL has placed in Intelsat throughout our 10-year relationship,” said Dave Bijur, senior vice president of Commercial for Intelsat Commercial Aviation. “JAL was Intelsat’s first non-U.S. commercial aviation customer, and we look forward to continuing to support JAL’s market-leading inflight connectivity service in Japan where their guests enjoy free service.” In addition to the fleet of Boeing 737s and 767s, JAL’s subsidiary airline, J-AIR Co. Lt

Discover ® Global Network Study Finds 93% of Global Fintechs Increased Reliance on Payment Networks Given the Current Economic Environment6.6.2023 07:02:00 CEST | Press release

Today, Discover shared a portion of the third annual Fintech State of the Union, the most comprehensive study of its kind in the industry, providing global perspectives from consumers, fintech vendors, and venture capitalists. The research study commissioned by Discover Global Network with 451 Research of S&P Global Market Intelligence surveyed global fintechs to identify emerging digital payments trends shaping the fintech ecosystem. Reliance on Payments Networks is Strong for Fintechs Per the study, fintechs are dependent on payments networks, with 93% saying the current economic environment has increased their business’s reliance on payments networks. Fintechs are looking for payments partners who are flexible (44%) and innovative (44%). Fintechs also say they benefit from payment networks the most through financial investment (42%), access to customers (38%), and technology enablement (38%). “As a payments network, it’s exciting to see both fintechs and venture capitalists lean int

Carbios Aims to be a Leader in Growing r-PET Market with an Ambition to Capture 8 to 12% Share by 2035 Through Licensing Model6.6.2023 06:45:00 CEST | Press release

Regulatory News: Carbios (Euronext Growth Paris: ALCRB), a biotech company pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, will hold its 2023 Strategic Update today at 2pm CET in which it provides details of its business model for 2030 and 2035. Carbios announces its ambition to be a leading player in the global r-PET market by capturing between 4 and 8% of market share by 2030 and between 8 and 12% by 2035. CLICK HERE TO JOIN THE WEBCAST AT 2pm CET OR TO VIEW THE REPLAY Emmanuel Ladent – Chief Executive Officer and the Carbios Leadership team 6 June 2023, from 2pm CET to 4pm CET (Paris Time) https://edge.media-server.com/mmc/p/u2qw4cir France Dial-in: +33 170918704 / UK Dial-in: +44 1 212818004 1. A VALUE-CREATING BUSINESS MODEL Carbios’ business model, based on the licensing of its unique PET biorecycling technology2, relies on a CapEx lean approach and 3 sources of revenue (upfront payments and two recur